SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending as investors closely monitor the progress of Blarcamesine, with an oral explanation scheduled with the CHMP. Community members express anticipation and speculate on potential approval, while also noting short selling activity. Some traders believe the market is underestimating the drug's potential, citing strong data and unmet needs in Alzheimer's treatment.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

GLTO is trending as traders discuss its potential for another run, fueled by a small float and high volatility. Community members are debating entry points, profit-taking strategies, and the possibility of a short squeeze. Some are comparing it to other recent high-flying stocks with similar setups.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

OSCR is trending downwards as investors react to potential changes in ACA subsidies and broader sector headwinds affecting healthcare stocks. The community is actively debating the impact of these changes on Oscar Health's business model, with some seeing it as a buying opportunity due to long-term growth potential and oversold conditions, while others express concerns about profitability and ACA reliance. Traders are closely monitoring key support levels and awaiting further news on government actions regarding healthcare.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

MannKind is trending due to concerns over pipeline setbacks, particularly the discontinuation of the ICoN-1 clinical trial, which has fueled discussions about leadership and strategic direction. The community is expressing frustration with the CEO and questioning past decisions, with some calling for new leadership or a potential acquisition. Despite revenue growth from existing partnerships, skepticism remains about the company's ability to execute on its pipeline and deliver shareholder value.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending amid discussions around its potential acquisition of Northern Data and its implications for GPU capacity and AI capabilities. Community members are weighing the potential for a short squeeze, given the high short interest and the involvement of figures like Tether and the Trump team. Some express frustration with the stock's performance and leadership, while others remain optimistic about Rumble's long-term prospects in the media and cloud space.

Movano, Inc. is a health-focused technology company. The firm uses non-invasive technology to enable individuals and their healthcare partners to measure and manage their health conditions. It offers solutions through the app, the cloud, the wearable, and the sensor. The company was founded by Michael Aaron Leabman in January 2018 and is headquartered in Pleasanton, CA.

Movano Inc

Movano (MOVE) is trending due to news of Nasdaq granting an extension to regain listing compliance, sparking significant community interest and heavy trading volume. Community discussions revolve around potential price targets and whether the stock can sustain its upward momentum, with some anticipating a squeeze. The stock's low float and history of volatility are also contributing to the heightened attention.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending following impressive Q3 results, including exceeding EPS and revenue expectations, which has sparked a surge in pre-market trading. The community is focused on the company's strong fundamentals, low float, and potential short squeeze, with many believing the stock is currently undervalued. Bullish sentiment is fueled by raised full-year guidance and comparisons to competitors, while some express concern over potential market volatility and historical price patterns.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

$GALT is trending due to growing excitement surrounding presentations at the AASLD Liver Meeting in November, where Belapectin's potential in treating MASH cirrhosis will be highlighted. The community is actively discussing the possibility of a buyout or partnership, particularly with companies seeking to enhance their GLP-1 portfolios, and speculating on a potential short squeeze fueled by high short interest.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

PLTR is trending as traders debate the impact of Michael Burry's short position and potential government contracts on its valuation. The reopening of the government is seen as a potential catalyst, fueling a battle between bulls and bears. Community members are actively discussing price targets and the stock's long-term prospects in the AI sector.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending amid an escalating bidding war with Novo Nordisk to acquire Metsera, a company focused on obesity drug development, with community discussion centered on whether Pfizer is overpaying. News of Pfizer's Q3 earnings, which beat expectations but revealed weakness in key areas, is also driving conversation, with some investors expressing frustration over the stock's limited upward movement despite positive financial results. Broader market context involves potential rotation into undervalued healthcare stocks and speculation about strategic acquisitions in the obesity treatment space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$EPWK  i have been doing dd all day on ChatGPT:

Setup looks primed for a move. The company has an upcoming 20-F filing due this week, a clear catalyst that usually sparks volatility in low-float China ADRs. Shareholders approved an RS authorization (2-for-1 → 100-for-1) valid for one year but it hasn’t been executed, so if price recovers above $1 it won’t be needed. Current float is about 40 M with volume steadily climbing (30–40 M avg), forming a base around $0.07–$0.09. If the 20-F shows decent cash and no RS execution, a run toward $0.3-$0.6 is realistic; a mention of dilution or RS timing could cap it. Either way, the chart and catalyst suggest big volatility ahead.

Brandon

StockTwits for iOS

EPWK Holdings Ltd

  i have been doing dd all day on ChatGPT:

Setup looks primed for a move. The company has an upcoming 20-F filing due this week, a clear catalyst that usually sparks volatility in low-float China ADRs. Shareholders approved an RS authorization (2-for-1 → 100-for-1) valid for one year but it hasn’t been executed, so if price recovers above $1 it won’t be needed. Current float is about 40 M with volume steadily climbing (30–40 M avg), forming a base around $0.07–$0.09. If the 20-F shows decent cash and no RS execution, a run toward $0.3-$0.6 is realistic; a mention of dilution or RS timing could cap it. Either way, the chart and catalyst suggest big volatility ahead.

Sas T

@Tuktuskins I agree the upside is super attractive. They likely don’t announce the RS before the meeting with the SEC. Should be in around 4 weeks. Plenty of time to pop shorts like pimples. You excited?

Joel Lopez

 I agree the upside is super attractive. They likely don’t announce the RS before the meeting with the SEC. Should be in around 4 weeks. Plenty of time to pop shorts like pimples. You excited?

Jokair

@Jokair Very! that’s what I’m thinking too. RS probably won’t happen until after the SEC meeting, and if the 20-F drops clean with no dilution or warning language, it gives plenty of room for momentum to build. The float’s light, volume’s been great past two weeks and this could easily squeeze. But I find the lack of people’s interest discouraging, there is no buzz on twitter, reddit even this thread is kinda dead.

 Very! that’s what I’m thinking too. RS probably won’t happen until after the SEC meeting, and if the 20-F drops clean with no dilution or warning language, it gives plenty of room for momentum to build. The float’s light, volume’s been great past two weeks and this could easily squeeze. But I find the lack of people’s interest discouraging, there is no buzz on twitter, reddit even this thread is kinda dead.

@Tuktuskins Totally agree. Even after a nearly 200% move a week or so ago. Makes you wonder, right? People can be quietly watching boards too. They don’t all comment even thought it can be helpful to do so.

 Totally agree. Even after a nearly 200% move a week or so ago. Makes you wonder, right? People can be quietly watching boards too. They don’t all comment even thought it can be helpful to do so.

@Jokair I agree their insights would be extremely helpful. What is your price prediction by the way?

 I agree their insights would be extremely helpful. What is your price prediction by the way?

@Tuktuskins Not $1. Be realistic. It did .0876 the other night in the blink of an eye.

 Not $1. Be realistic. It did .0876 the other night in the blink of an eye.